Home/Filings/4/A/0001127602-24-030049
4/A//SEC Filing

Joyner J. David 4/A

Accession 0001127602-24-030049

CIK 0000064803other

Filed

Dec 25, 7:00 PM ET

Accepted

Dec 26, 4:11 PM ET

Size

9.4 KB

Accession

0001127602-24-030049

Insider Transaction Report

Form 4/AAmended
Period: 2024-11-30
Joyner J. David
EVP, Sales & Account Services
Transactions
  • Award

    Premium Stock Appreciation Right

    2024-11-30$71.82/sh+492,537$35,374,007492,537 total
    Exercise: $71.82From: 2025-11-30Exp: 2031-11-30Common Stock (492,537 underlying)
  • Award

    Premium Stock Option

    2024-11-30$71.82/sh+1,000,000$71,820,0001,000,000 total
    Exercise: $71.82From: 2025-11-30Exp: 2031-11-30Common Stock (1,000,000 underlying)
Holdings
  • Common Stock (Restricted)

    44,241
  • Common Stock

    40,681
Footnotes (1)
  • [F1]On December 20, 2024, the Issuer made certain administrative modifications to the Reporting Person's November 30, 2024 grant agreement, confirming that the Reporting Person was granted a stock option to acquire 1,000,000 shares of Issuer common stock and a stock-settled stock appreciation right ("SAR") with respect to 492,537 shares of Issuer common stock, each at a premium exercise or grant price, as applicable, of $71.82. Both the option and the SAR become exercisable in three equal annual installments, with the first installment vesting on November 30, 2025. No change was made to the aggregate grant date value of the award, as reflected in the original Form 4 filed by the Reporting Person on December 3, 2024.

Issuer

CVS HEALTH Corp

CIK 0000064803

Entity typeother

Related Parties

1
  • filerCIK 0001515598

Filing Metadata

Form type
4/A
Filed
Dec 25, 7:00 PM ET
Accepted
Dec 26, 4:11 PM ET
Size
9.4 KB